Forward Pharma (FWP): Reiterating Buy Ahead Of Next Week's Litigation - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success
November 25, 2016 8:52 AM ESTLeerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More
Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird
November 23, 2016 10:40 AM ESTBaird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,
Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More
Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness
November 23, 2016 9:48 AM ESTMizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.
Syed commented, "While we are... More
Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
November 23, 2016 9:27 AM ESTBMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.
Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failure, as we... More
